Vanda Pharmaceuticals | VNDA - Ordinary Share Capital


Vanda Pharmaceuticals reported $58K in Ordinary Share Capital for its fiscal quarter ending in December of 2024.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
Akebia Therapeutics USD 2K 0 Mar/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Anika Therapeutics USD 143K 1000 Mar/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
AstraZeneca USD 1.55B 206K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Esperion Therapeutics USD 112K 11K Sep/2023
Halozyme Therapeutics USD 117.52M 98K Sep/2025
Heron Therapeutics USD 1.52M 14K Sep/2024
Insmed USD 212.58M 210.76M Sep/2025
J&J USD 2.41B 584K Sep/2025
Ligand Pharmaceuticals USD 20K 0 Mar/2025
Merck USD 2.49B 15.79M Sep/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Moderna USD 391M 2M Sep/2025
Novartis USD 1.92B 17.06M Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Puma Biotechnology USD 5K 0 Jun/2024
Takeda JPY 1.58B 2K Dec/2025
Teva Pharmaceutical Industries USD 1.15B 0 Dec/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Veracyte USD 78.67M 73K Sep/2025